Evaluation and Performance Measures:
6.0 Network Development Measures

Regional Ebola and Other Special Pathogen Treatment Center COVID-19 Preparedness and Response Activities Administrative Supplement Performance Measures

Operational Intent: These performance measures examine the activities that have been implemented to achieve the following outcomes:

Support continued planning, development, and implementation of a national system for special pathogen patient care10, including engaging state and jurisdiction special pathogentreatment centers; and other health care facilities (including but not limited to settings suchas nursing homes, residential care facilities, EMS, and 911 call centers)
Support NETEC in their activities as a ‘force amplifier’ in their region

Required Program Performance Measure	Data Point(s)	Data Entity	Calculation
PM 15: Promising practices developed to support the continued planning, development, and implementation of a national system for specialpathogen patient care	What promising practices have you developed to support the continued planning, development, and implementation of a national system for special pathogen patient care using RESPTC COVID-19 Preparedness and Response Activities Administrative Supplement funds? What impact did you achieve? (Free response – 750-character response length)	RESPTC	Qualitative description of promising practices and impact achieved
PM 16: Challenges encountered by RESPTCs in the continued planning, development, and implementation of a national system for specialpathogen patient care	What specific challenges have you encountered regarding your ability to plan, develop, and implement a national system for special pathogen care using RESPTC COVID-19 Preparedness and Response Activities Administrative Supplement funds? (Select all that apply) Coordinating andcommunicating across facilities and partners (freeresponse – 300-character response length) Incentivizing participationfrom key stakeholders(free response – 300-character response length) Aligning regional workplans with national NETEC initiatives (freeresponse – 300-character response length) Other (free response –600-character response length) Please briefly describe the impact of these challenges (free response – 600-character response length).	RESPTC	Number of RESPTCs reporting each challenge Qualitative description of challenges and impact of challenges
PM 17: Promising practices implemented byRESPTCs to access and use information and resources from NETEC	Which of the following promising practices did your RESPTC employ to access and use NETEC information and resources using RESPTC COVID-19 Preparedness and Response Activities Administrative Supplement funds? (Select all that apply) Utilized NETEC resources to improve operations andclinical outcomes within my RESPTC Shared NETEC resources with other health carefacilities, organizations,and staff Participated in the provision of technical assistance by NETEC Subject Matter Experts (SMEs) for facilities in my region Utilized NETECinfrastructure to supportcapacity and capability to participate in emergency clinical research^[11] Other (free response –500-character responselength)	RESPTC	Number of RESPTCs implementing each listed promising practice
PM 18: Promising practices used that promote coordination and collaboration between RESPTCS and other regional disaster response organizations^[12]	What promising practices did your organization use to collaborate with other regional organizations for disaster response (e.g., Regional Disaster Health Response System demonstration sites, Health Care Coalitions, etc.) using RESPTC COVID-19 Preparedness and Response Activities Administrative Supplement funds? What impact did you achieve? (Free response – 750-character response length)	RESPTC	Number of RESPTCs collaborating with other regional organizations Qualitative description of promising practices, partners, and impact achieved

^11. The Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities Cooperative Agreement (CFDA #93.817) Part B permits the Regional Ebola and Other Special Pathogen Treatment Centers to participate in clinical research, clinical trials, and experimental protocols, if appropriate, but recipients may not use cooperative agreement funds for research.

^12. Note: A similar optional question also appears in performance measures for the RESPTC FY20 Administrative Supplement. Please limit this particular response to COVID-19-specific activities and outcomes funded by the RESPTC COVID-19 Preparedness and Response Activities Administrative Supplement.